The presence or absence of autoantibodies against citrullinated proteins (ACPAs) distinguishes two main groups of rheumatoid arthritis (RA) patients with different etiologies, prognoses, disease severities, and, presumably, disease pathogenesis. The heterogeneous responses of RA patients to various biologics, even among ACPA-positive patients, emphasize the need for further stratification of the patients. We used high-density protein array technology for fingerprinting of ACPA reactivity. Identification of the proteome recognized by ACPAs may be a step to stratify RA patients according to immune reactivity. Pooled plasma samples from 10 anti-CCP-negative and 15 anti-CCP-positive RA patients were assessed for ACPA content using a modified protein microarray containing 1631 different natively folded proteins citrullinated in situ by protein arginine deiminases (PADs) 2 and PAD4. IgG antibodies from anti-CCP-positive RA plasma showed high-intensity binding to 87 proteins citrullinated by PAD2 and 99 proteins citrullinated by PAD4 without binding significantly to the corresponding native proteins. Curiously, the binding of IgG antibodies in anti-CCP-negative plasma was also enhanced by PAD2- and PAD4-mediated citrullination of 29 and 26 proteins, respectively. For only four proteins, significantly more ACPA binding occurred after citrullination with PAD2 compared to citrullination with PAD4, while the opposite was true for one protein. We demonstrate that PAD2 and PAD4 are equally efficient in generating citrullinated autoantigens recognized by ACPAs. Patterns of proteins recognized by ACPAs may serve as a future diagnostic tool for further subtyping of RA patients.

Department of Clinical Immunology Aalborg University Hospital Aalborg Denmark

Department of Clinical Medicine Aalborg University Aalborg Denmark

Department of Health Science and Technology Aalborg University Fredrik Bajers Vej 5 9220 Aalborg Denmark

Department of Integrative Biomedical Sciences and Institute of Infectious Disease and Molecular Medicine University of Cape Town Cape Town South Africa

Institute for Inflammation Research Center for Rheumatology and Spine Diseases Copenhagen University Hospital Rigshospitalet Copenhagen Denmark

Institute of Rheumatology and Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Sino Danish College University of Chinese Academy of Sciences Beijing China

Zobrazit více v PubMed

Arend WP, Firestein GS. Pre-rheumatoid arthritis: Predisposition and transition to clinical synovitis. Nat. Rev. Rheumatol. 2012;8(10):573–586. doi: 10.1038/nrrheum.2012.134. PubMed DOI

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Investig. 1998;101(1):273–281. doi: 10.1172/JCI1316. PubMed DOI PMC

Schellekens GA, Visser H, de Jong BAW, Van Den Hoogen FHJ, Hazes JMW, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43(1):155–163. doi: 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3. PubMed DOI

Nielen MMJ, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MHMT, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–386. doi: 10.1002/art.20018. PubMed DOI

Tracy A, Buckley CD, Raza K. Pre-symptomatic autoimmunity in rheumatoid arthritis: When does the disease start? Semin. Immunopathol. 2017;39(4):423–435. doi: 10.1007/s00281-017-0620-6. PubMed DOI PMC

Seegobin, S. D. et al. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: Secondary analysis of a randomized controlled trial. Arthritis Res. Ther. 16(1):R13. http://arthritis-research.com/content/16/1/R13 (2014). PubMed PMC

van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, Toes REM, Huizinga TWJ. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res. Ther. 2005;7(5):R949–R958. doi: 10.1186/ar1767. PubMed DOI PMC

Vossenaar ER, Zendman AJW, van Venrooij WJ, Pruijn GJM. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. BioEssays. 2003;25(11):1106–1118. doi: 10.1002/bies.10357. PubMed DOI

Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Méchin M-C, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007;56(11):3541–3553. doi: 10.1002/art.22983. PubMed DOI

Blachère NE, Parveen S, Frank MO, Dill BD, Molina H, Orange DE. High-titer rheumatoid arthritis antibodies preferentially bind fibrinogen citrullinated by peptidylarginine deiminase 4. Arthritis Rheumatol. 2017;69(5):986–995. doi: 10.1002/art.40035. PubMed DOI PMC

Damgaard D, Bawadekar M, Senolt L, Stensballe A, Shelef MA, Nielsen CH. Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3. Pizzo S V, editor. PLoS One. 2018;13(8):0203214. doi: 10.1371/journal.pone.0203214. PubMed DOI PMC

van Beers JJ, Raijmakers R, Alexander L-E, Stammen-Vogelzangs J, Lokate AM, Heck AJ, et al. Mapping of citrullinated fibrinogen B-cell epitopes in rheumatoid arthritis by imaging surface plasmon resonance. Arthritis Res. Ther. 2010;12(6):R219. doi: 10.1186/ar3205. PubMed DOI PMC

Willis VC, Banda NK, Cordova KN, Chandra PE, Robinson WH, Cooper DC, et al. Protein arginine deiminase 4 inhibition is sufficient for the amelioration of collagen-induced arthritis. Clin. Exp. Immunol. 2017;188(2):263–274. doi: 10.1111/cei.12932. PubMed DOI PMC

Moscarello MA, Lei H, Mastronardi FG, Winer S, Tsui H, Li Z, et al. Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis. Dis. Model Mech. 2013;6(2):467–478. doi: 10.1242/dmm.010520. PubMed DOI PMC

Mohanan S, Cherrington BD, Horibata S, McElwee JL, Thompson PR, Coonrod SA. Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem. Res. Int. 2012;2012:895343. doi: 10.1155/2012/895343. PubMed DOI PMC

Ishigami A, Ohsawa T, Hiratsuka M, Taguchi H, Kobayashi S, Saito Y, et al. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer’s disease. J. Neurosci. Res. 2005;80(1):120–128. doi: 10.1002/jnr.20431. PubMed DOI

Aggarwal A. Role of autoantibody testing. Best Pract. Res. Clin. Rheumatol. 2014;28(6):907–920. doi: 10.1016/j.berh.2015.04.010. PubMed DOI

Takeuchi T. Biomarkers as a treatment guide in rheumatoid arthritis. Clin. Immunol. 2018;186:59–62. doi: 10.1016/j.clim.2017.07.019. PubMed DOI

Soe HJ, Yong YK, Al-Obaidi MMJ, Raju CS, Gudimella R, Manikam R, et al. Identifying protein biomarkers in predicting disease severity of dengue virus infection using immune-related protein microarray. Medicine (Baltimore) 2018;97(5):6–12. doi: 10.1097/MD.0000000000009713. PubMed DOI PMC

Poulsen TBG, et al. Identification of novel native autoantigens in rheumatoid arthritis. Biomedicines. 2020;8(6):141. doi: 10.3390/biomedicines8060141. PubMed DOI PMC

Poulsen TBG, Karamehmedovic A, Aboo C, Jørgensen MM, Yu X, Fang X, et al. Protein array-based companion diagnostics in precision medicine. Expert Rev. Mol. Diagn. 2020;20(12):1183–1198. doi: 10.1080/14737159.2020.1857734. PubMed DOI

Konig MF, Giles JT, Nigrovic PA, Andrade F. Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. Ann. Rheum. Dis. 2016;75(11):2022–2028. doi: 10.1136/annrheumdis-2015-208529. PubMed DOI

Wang X, Chen P, Cui J, Yang C, Du H. Biochemical and biophysical research communications keratin 8 is a novel autoantigen of rheumatoid arthritis. Biochem. Biophys. Res. Commun. 2015;465(4):665–669. doi: 10.1016/j.bbrc.2015.07.161. PubMed DOI

Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: Association with HLA-DRB1 alleles. Ann. Rheum. Dis. 2009;68(5):736–743. doi: 10.1136/ard.2008.091355. PubMed DOI

Schwenzer A, Jiang X, Mikuls TR, Payne JB, Sayles HR, Quirke A-M, et al. Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis. Ann. Rheum. Dis. 2016;75(10):1876–1883. doi: 10.1136/annrheumdis-2015-208495. PubMed DOI PMC

Van Steendam K, Tilleman K, Deforce D. The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology. 2011;50(5):830–837. doi: 10.1093/rheumatology/keq419. PubMed DOI PMC

Kurowska W, Kuca-Warnawin EH, Radzikowska A, Maśliński W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Cent. J. Immunol. 2017;42(4):390–398. doi: 10.5114/ceji.2017.72807. PubMed DOI PMC

Karthikeyan K, Barker K, Tang Y, Kahn P, Wiktor P, Brunner A, et al. A contra capture protein array platform for studying post-translationally modified (PTM) Auto-antigenomes. Mol. Cell Proteom. 2016;15(7):2324–2337. doi: 10.1074/mcp.M115.057661. PubMed DOI PMC

Sahlström P, Hansson M, Steen J, Amara K, Titcombe PJ, Forsström B, et al. Different hierarchies of anti-modified protein autoantibody reactivities in rheumatoid arthritis. Arthritis Rheumatol. 2020;72(10):1643–1657. doi: 10.1002/art.41385. PubMed DOI

Damgaard D, Bjørn ME, Jensen PØ, Nielsen CH. Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase. J. Enzyme Inhib. Med. Chem. 2017;32(1):1203–1208. doi: 10.1080/14756366.2017.1368505. PubMed DOI PMC

Nakayama-Hamada M, Suzuki A, Kubota K, Takazawa T, Ohsaka M, Kawaida R, et al. Comparison of enzymatic properties between hPADI2 and hPADI4. Biochem. Biophys. Res. Commun. 2005;327(1):192–200. doi: 10.1016/j.bbrc.2004.11.152. PubMed DOI

Vossenaar ER, Radstake TRD, van der Heijden A, van Mansum MAM, Dieteren C, de Rooij D-J, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 2004;63(4):373–381. doi: 10.1136/ard.2003.012211. PubMed DOI PMC

Damgaard D, Senolt L, Nielsen MF, Pruijn GJ, Nielsen CH. Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen. Arthritis Res. Ther. 2014;16(6):498. doi: 10.1186/s13075-014-0498-9. PubMed DOI PMC

Ioan-Facsinay A, El-Bannoudi H, Scherer HU, van der Woude D, Menard HA, Lora M, et al. Anti-CCP antibodies are a collection of ACPA that are cross-reactive to multiple citrullinated antigens. Ann. Rheum. Dis. 2010;69(Suppl 2):A8–A8. doi: 10.1136/ard.2010.129577s. DOI

Ge C, Xu B, Liang B, Lönnblom E, Lundström SL, Zubarev RA, et al. Structural basis of cross-reactivity of anti-citrullinated protein antibodies. Arthritis Rheumatol. 2019;71(2):210–221. doi: 10.1002/art.40698. PubMed DOI

Trier NH, Leth ML, Hansen PR, Houen G. Cross-reactivity of a human IgG 1 anticitrullinated fibrinogen monoclonal antibody to a citrullinated profilaggrin peptide. Protein Sci. 2012;21(12):1929–1941. doi: 10.1002/pro.2178. PubMed DOI PMC

Reed E, Hedström AK, Hansson M, Mathsson-Alm L, Brynedal B, Saevarsdottir S, et al. Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res. Ther. 2020;22(1):170. doi: 10.1186/s13075-020-02191-2. PubMed DOI PMC

Somers K, Geusens P, Elewaut D, De Keyser F, Rummens J-L, Coenen M, et al. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J. Autoimmun. 2011;36(1):33–46. doi: 10.1016/j.jaut.2010.10.003. PubMed DOI

De Winter LM, Hansen WLJ, van Steenbergen HW, Geusens P, Lenaerts J, Somers K, et al. Autoantibodies to two novel peptides in seronegative and early rheumatoid arthritis. Rheumatology. 2016;55(8):1431–1436. doi: 10.1093/rheumatology/kew198. PubMed DOI

Wagner CA, Sokolove J, Lahey LJ, Bengtsson C, Saevarsdottir S, Alfredsson L, et al. Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: Association with cigarette smoking and HLA-DRB1 ‘shared epitope’ alleles. Ann. Rheum. Dis. 2013;74(3):579–586. doi: 10.1136/annrheumdis-2013-203915. PubMed DOI PMC

Strollo R, Vinci C, Napoli N, Pozzilli P, Ludvigsson J, Nissim A. Antibodies to post-translationally modified insulin as a novel biomarker for prediction of type 1 diabetes in children. Diabetologia. 2017;60(8):1467–1474. doi: 10.1007/s00125-017-4296-1. PubMed DOI PMC

Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J. Exp. Med. 1997;185(5):843–54. doi: 10.1084/jem.185.5.843. PubMed DOI PMC

Wegner N, Wait R, Sroka A, Eick S, Nguyen K-A, Lundberg K, et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2662–2672. doi: 10.1002/art.27552. PubMed DOI PMC

Konig MF, Paracha AS, Moni M, Bingham CO, Andrade F. Defining the role of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. Ann. Rheum. Dis. 2015;74(11):2054–2061. doi: 10.1136/annrheumdis-2014-205385. PubMed DOI PMC

de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, et al. Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Res. Ther. 2018;20(1):33. doi: 10.1186/s13075-018-1520-4. PubMed DOI PMC

Lal P, Su Z, Holweg CTJ, Silverman GJ, Schwartzman S, Kelman A, et al. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum. 2011;63(12):3681–3691. doi: 10.1002/art.30596. PubMed DOI

Hamaguchi Y. Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis. J. Dermatol. 2010;37(1):42–53. doi: 10.1111/j.1346-8138.2009.00762.x. PubMed DOI

Liang Z, Long F, Wang F, Yang Y, Xiao J, Deng K, et al. Identification of clinically relevant subgroups of COPD based on airway and circulating autoantibody profiles. Mol. Med. Rep. 2019 doi: 10.3892/mmr.2019.10498. PubMed DOI

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi: 10.1002/art.27584. PubMed DOI

Duarte J, Serufuri J, Mulder N, Blackburn J. Bioinformatics of Human Proteomics, Vol ***3. Springer; 2013. pp. 39–74.

Bennike TB, et al. Neutrophil extracellular traps in ulcerative colitis. Inflamm. Bowel Dis. 2015;21(9):2052–67. doi: 10.1097/MIB.0000000000000460. PubMed DOI PMC

Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 2019;47(D1):D442–D450. doi: 10.1093/nar/gky1106. PubMed DOI PMC